Tandavanitj, R., Setthapramote, C., De Lorenzo, G. , Sanchez-Velazquez, R., Clark, J. J., Rocchi, M., McInnes, C., Kohl, A. and Patel, A. H. (2024) Virus-like particles of louping ill virus elicit potent neutralizing antibodies targeting multimers of viral envelope protein. Vaccine, (doi: 10.1016/j.vaccine.2024.03.008) (In Press)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
321983.pdf - Published Version Available under License Creative Commons Attribution. 3MB |
Abstract
Louping ill virus (LIV) is a tick-borne flavivirus that predominantly causes disease in livestock, especially sheep in the British Isles. A preventive vaccine, previously approved for veterinary use but now discontinued, was based on an inactivated whole virion that likely provided protection by induction of neutralizing antibodies recognizing the viral envelope (E) protein. A major disadvantage of the inactivated vaccine was the need for high containment facilities for the propagation of infectious virus, as mandated by the hazard group 3 status of the virus. This study aimed to develop high-efficacy non-infectious protein-based vaccine candidates. Specifically, soluble envelope protein (sE), and virus-like particles (VLPs), comprised of the precursor of membrane and envelope proteins, were generated, characterized, and studied for their immunogenicity in mice. Results showed that the VLPs induced more potent virus neutralizing response compared to sE, even though the total anti-envelope IgG content induced by the two antigens was similar. Depletion of anti-monomeric E protein antibodies from mouse immune sera suggested that the neutralizing antibodies elicited by the VLPs targeted epitopes spanning the highly organized structure of multimer of the E protein, whereas the antibody response induced by sE focused on E monomers. Thus, our results indicate that VLPs represent a promising LIV vaccine candidate.
| Item Type: | Articles |
|---|---|
| Additional Information: | This research was funded by the Government Pharmaceutical Organization, Thailand (R.T.), Faculty of Medicine Vajira Hospital, Navamindradhiraj University (C.S.) and by the UK Medical Research Council grants MC_UU12014/2 (A.H.P) and MC_UU_12014/8 and MC_UU_00034/4 (A.K.). |
| Keywords: | Louping ill virus, virus-like particles, VLPs, protein-based vaccines, neutralizing, antibodies. |
| Status: | In Press |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Sanchez Velazquez, Ricardo and De Lorenzo, Dr Giuditta and Rocchi, Dr Mara and Tandavanitj, Rapeepat and CLARK, Jordan and Setthapramote, Dr Chayanee and Patel, Professor Arvind and Kohl, Professor Alain |
| Creator Roles: | Tandavanitj, R.Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft Setthapramote, C.Formal analysis, Investigation, Methodology, Resources, Supervision, Visualization, Writing – original draft De Lorenzo, G.Formal analysis, Investigation, Methodology, Validation, Supervision Sanchez Velazquez, R.Methodology, Validation CLARK, J.Formal analysis, Investigation, Methodology, Resources Rocchi, M.Resources Kohl, A.Conceptualization, Funding acquisition, Resources, Writing – original draft Patel, A.Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – original draft |
| Authors: | Tandavanitj, R., Setthapramote, C., De Lorenzo, G., Sanchez-Velazquez, R., Clark, J. J., Rocchi, M., McInnes, C., Kohl, A., and Patel, A. H. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine College of Medical Veterinary and Life Sciences > School of Infection & Immunity College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research |
| Journal Name: | Vaccine |
| Publisher: | Elsevier |
| ISSN: | 0264-410X |
| ISSN (Online): | 1873-2518 |
| Published Online: | 08 March 2024 |
| Copyright Holders: | Copyright © 2024 The Authors |
| First Published: | First published in Vaccine 2024 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information